EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma

R V Rawson, N G Maher, A M Menzies, S N Lo, N Mesbah Ardakani, L A Jackett, I A Vergara, T E Pennington, K F Shannon, S Ch'ng, M Gonzalez, E M Burton und 19 weitere

Annals of Oncology · 2026

DOI: 10.1016/j.annonc.2025.10.1237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Oncology, 2026. Verfasst von R V Rawson und 30 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australi…. Hauptthemen laut MEDLINE: Melanoma, Neoadjuvant Therapy, Skin Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, University of Sydney, Melanoma Institute Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Neoadjuvant immunotherapy produces event-free survival advantage over adjuvant therapy for patients with surgically resectable macroscopic stage IIIB/C/D melanoma. Pathological response, determined as percentage residual viable tumor (% RVT), provides critical prognostic information and informs management decisions. Here, we assessed accuracy of %RVT calculation when reduced tumor bed (TB) was examined and leverage these results proposing streamlined protocols for pathological examination. PATIENTS AND METHODS: Comprehensive histopathological examination was carried out on 134 patient specimens after neoadjuvant immunotherapy with ipilimumab and nivolumab. Impact on %RVT when evaluating less TB than recommended by the initial International Neoadjuvant Melanoma Consortium (INMC) protocol was assessed. Firstly, % RVT of each case was recalculated using seven modified protocols and compared with % RVT obtained under INMC protocol. Next, a simulation study was carried out recalculating % RVT by random sampling 50%, 33%, and 25% of TB slides per specimen. RESULTS: > 0.97) for all the modified protocols and >90% accuracy in five protocols. Accuracy of major pathological response (MPR)/non-MPR and pathological response category classification was ≥96% in six protocols. The decrease in average slides examined per specimen ranged from 9% to 58%. In total, 85%, 79%, and 74% of simulations recalculating %RVT were within 5% of the INMC calculation when 50%, 33%, and 25% of TB slides were examined, respectively. If TB slide examination is capped at 20, %RVT calculation remains 93% accurate. CONCLUSIONS: TB embedded for histopathological examination in neoadjuvant stage IIIB/C/D melanoma specimens can be reduced without significantly compromising accuracy of %RVT calculation. We recommend an updated pathological assessment protocol: lymph nodes ≤3 cm examined in entirety; macroscopically involved lymph nodes >3 cm should have a modified examination protocol of at least a full cross-sectional transverse slice. Capping TB slides examined at 20 appears reasonable. This refined approach results in high accuracy and significant reduction in the slides examined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaNeoadjuvant TherapySkin NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansNeoplasm StagingIpilimumabNivolumabFemaleMaleMiddle AgedNeoplasm, ResidualPrognosisImmunotherapyAgedAdult

Stichwörter der Autor:innen

melanomaneoadjuvantpathological responsetumor bed

Substanzen

IpilimumabNivolumab

Autor:innen und Institutionen

  • Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia; NSW Health Patholo…
  • Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Royal North Shore, Sydney, Australia; The Mater Hospital, Wollstone…
  • Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia.
  • Department of Anatomical Pathology, PathWest Laboratory Medicine, QEII Medical Centre, Perth, Australia.
  • Peter MacCallum Cancer Centre, Melbourne, Australia.

Förderung

  • National Health and Medical Research Council
  • University of Sydney
  • Melanoma Institute Australia

Zitieren

APA

Rawson, R. V., Maher, N. G., Menzies, A. M., Lo, S. N., Mesbah Ardakani, N., Jackett, L. A., Vergara, I. A., Pennington, T. E., Shannon, K. F., Ch'ng, S., Gonzalez, M., Burton, E. M., Lucas, M. W., Reijers, I. L. M., Rozeman, E. A., Gyorki, D. E., Sandhu, S., Carlino, M. S., Howle, J., …, & Scolyer, R. A. (2026). Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma. Annals of Oncology. https://doi.org/10.1016/j.annonc.2025.10.1237

Vancouver

Rawson RV, Maher NG, Menzies AM, Lo SN, Mesbah Ardakani N, Jackett LA, et al. Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma. Annals of Oncology. 2026. doi:10.1016/j.annonc.2025.10.1237

BibTeX
@article{Rawson2026,
  author = {Rawson, R V and Maher, N G and Menzies, A M and Lo, S N and Mesbah Ardakani, N and Jackett, L A and Vergara, I A and Pennington, T E and Shannon, K F and Ch'ng, S and Gonzalez, M and Burton, E M and Lucas, M W and Reijers, I L M and Rozeman, E A and Gyorki, D E and Sandhu, S and Carlino, M S and Howle, J and Khattak, M and Van der Westhuizen, A and Andrews, M C and Atkinson, V and van Akkooi, A C J and Spillane, A J and Saw, R P M and van de Wiel, B A and Blank, C U and Long, G V and Tetzlaff, M T and Scolyer, R A},
  title = {Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma},
  journal = {Annals of Oncology},
  year = {2026},
  doi = {10.1016/j.annonc.2025.10.1237}
}
Kostenlos starten →